This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Ovarian cancer	ATPase class VI type 11B (ATP11B)	<p>Mouse and cell culture studies suggest inhibiting ATP11B could help circumvent resistance to platinum chemotherapy in ovarian cancer. In a genomic analysis of a panel of ovarian cancer cell lines, cisplatin-resistant cells had greater ATP11B expression than cisplatin-sensitive lines. In a cisplatin-resistant ovarian cancer cell line, liposome-mediated delivery of <i>ATP11B</i>-targeted small interfering RNA increased cisplatin sensitivity compared with delivery of control siRNA. In multiple mouse xenograft models for cisplatin-resistant human ovarian cancer, cisplatin plus liposome-mediated delivery of <i>ATP11B</i>-targeted siRNA decreased tumor growth compared with cisplatin plus delivery of control siRNA. Next steps include further exploring the mechanisms underlying resistance to platinum chemotherapy.</p> <p>SciBX 6(16); doi:10.1038/scibx.2013.387 Published online April 25, 2013</p>	Patent application filed covering liposome-based siRNA delivery system; available for licensing from The University of Texas MD Anderson Cancer Center's Office of Technology Commercialization	<p>Moreno-Smith, M. <i>et al. J. Clin. Invest.</i>; published online April 15, 2013; doi:10.1172/JCI65425</p> <p>Contact: Anil K. Sood, The University of Texas MD Anderson Cancer Center, Houston, Texas e-mail: asood@mdanderson.org</p>